Skip to content

Trans-abdominal Fetal Pulse Oximetry; Tissue Light Scattering and Signal Integrity

Trans-abdominal Fetal Pulse Oximetry; Tissue Light Scattering and Signal Integrity

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04876846
Enrollment
9
Registered
2021-05-07
Start date
2021-04-24
Completion date
2025-11-11
Last updated
2025-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fetal Hypoxia

Brief summary

The overall purpose of this study is to evaluate maternal-fetal tissue light scattering properties. The objectives of the study are: (i) integrate established mathematical principles of oxygen saturation to model with increasing accuracy the body in a body problem of fetus in mother; similar to existing pulse oximeters, the calculations will be integrated into software in the final commercial product; (ii) obtain human measurements against which both computational models and animal data can be compared.

Detailed description

This is a prospective, observational, non-significant risk study. The study involves using non-invasive devices that measure fetal depth and tissue light scattering on the maternal abdomen. Ultrasound assessment will be performed, and multiple images taken at various locations on the abdomen. All images will be captured with minimal probe pressure applied to allow accurate ascertainment of depth. Images will be anonymized, and all study data will be coded with a unique identifier. Key maternal descriptive statistics will be recorded from the medical record including BMI, height, weight (kg), parity, age and gestational age. The ISS device is a customized commercial frequency domain oximeter (Imagent, ISS Inc.; http://www.iss.com/biomedical/instruments/imagent.html) with multiple laser sources and multiple detectors. This instrument is safe, uses non-ionizing radiation. The Raydiant Lumerah device is a non-invasive fetal pulse oximeter that measures fetal arterial oxygen saturation using safe, non-invasive, transabdominal near-infrared spectroscopy. The Lumerah device will be positioned on the maternal abdomen of women volunteers in the late 3rd trimester.

Interventions

DEVICEGEN 3 Monitoring of Fetus

Measurement of tissue light scatter in the body in body during late term pregnancy and evaluation of signal integrity

Sponsors

Raydiant Oximetry, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Women with singleton, healthy pregnancy at gestational age ≥ 36 weeks 2. Age \> 18 years 3. Willing to come in for testing outside of routine business hours (including Saturdays)

Exclusion criteria

1. Age \<18 2. Multiple gestation (twins, triplets) 3. Presentation other than vertex or breech 4. \< 36 weeks of gestation

Design outcomes

Primary

MeasureTime frameDescription
Fetal SignalAfter 36 weeks of pregnancyCorrelation of the fetal doppler signal with the ROSS device optional fetal signal.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026